Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
- 1 December 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 370 (9602) , 1847-1853
- https://doi.org/10.1016/s0140-6736(07)61780-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Japanese Encephalitis Outbreak, India, 2005Emerging Infectious Diseases, 2006
- Control of Japanese Encephalitis — Within Our Grasp?New England Journal of Medicine, 2006
- Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control studyThe Lancet, 2005
- Review on flavivirus vaccine development: Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, ThailandVaccine, 2005
- Yellow fever and Japanese encephalitis vaccines: indications and complicationsInfectious Disease Clinics of North America, 2005
- Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis AntigenThe Journal of Infectious Diseases, 2003
- Efficacy of single-dose SA 14–14–2 vaccine against Japanese encephalitis: a case control studyThe Lancet, 2001
- New initiatives for the control of Japanese encephalitis by vaccination:Vaccine, 2000
- Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control studyThe Lancet, 1996
- Protection against Japanese Encephalitis by Inactivated VaccinesNew England Journal of Medicine, 1988